TRAVERE THERAPEUTICS, INC. Realized Gains on Marketable Securities
TRAVERE THERAPEUTICS, INC. (TVTX) reported Realized Gains on Marketable Securities of $2.35 million for the 12-month period ending 2014-12-31, per its 10-K filed 2015-03-11.
Discontinued › Income Statement › Other Income
us-gaap:MarketableSecuritiesRealizedGainLoss · last filed 2015-07-09
- TRAVERE THERAPEUTICS, INC. marketable securities, realized gain (loss) for the quarter ending 2014-06-30 was -$370.18K.
- TRAVERE THERAPEUTICS, INC. marketable securities, realized gain (loss) for the quarter ending 2014-03-31 was -$4.66K.
- TRAVERE THERAPEUTICS, INC. marketable securities, realized gain (loss) for the quarter ending 2013-12-31 was $314.75K.
- TRAVERE THERAPEUTICS, INC. marketable securities, realized gain (loss) for the quarter ending 2013-09-30 was $59.74K.
- TRAVERE THERAPEUTICS, INC. marketable securities, realized gain (loss) for fiscal 2014 was $2.35M, a 527.38% increase from fiscal 2013.
- TRAVERE THERAPEUTICS, INC. marketable securities, realized gain (loss) for fiscal 2013 was $374.48K.
| Period end | Marketable Securities, Realized Gain (Loss) 3 month | Marketable Securities, Realized Gain (Loss) 3 month as first filed | Marketable Securities, Realized Gain (Loss) 6 month | Marketable Securities, Realized Gain (Loss) 9 month | Marketable Securities, Realized Gain (Loss) 9 month as first filed | Marketable Securities, Realized Gain (Loss) 12 month | Marketable Securities, Realized Gain (Loss) 12 month as first filed | Marketable Securities, Realized Gain (Loss) 31 month | Marketable Securities, Realized Gain (Loss) 31 month as first filed | Marketable Securities, Realized Gain (Loss) 34 month | Marketable Securities, Realized Gain (Loss) 34 month as first filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2014-12-31 | $2.35M 10-K · filed 2015-03-11 | ||||||||||
| 2014-06-30 | -$370.18K 10-Q · filed 2014-08-14 | -$374.84K 10-Q · filed 2014-08-14 | -$60.10K derived: sum of 3 quarters · filed 2015-07-09 | -$359.00 derived: sum of 4 quarters · filed 2015-07-09 | |||||||
| 2014-03-31 | -$4.66K 10-Q · filed 2014-05-15 | $310.08K derived: sum of 2 quarters · filed 2015-07-09 | $369.82K derived: sum of 3 quarters · filed 2015-07-09 | ||||||||
| 2013-12-31 | $314.75K derived: 10-K/A 12 month − 10-Q/A 9 month · filed 2015-07-09 | $374.48K derived: sum of 2 quarters · filed 2015-07-09 | $374.48K 10-K/A · filed 2015-07-09 | -$374.48K 10-K · filed 2014-03-28 | $374.48K 10-K/A · filed 2015-07-09 | -$374.48K 10-K · filed 2014-03-28 | |||||
| 2013-09-30 | $59.74K 10-Q/A · filed 2015-07-09 | -$59.74K 10-Q · filed 2013-11-13 | $59.74K 10-Q/A · filed 2015-07-09 | -$59.74K 10-Q · filed 2013-11-13 | $59.74K 10-Q/A · filed 2015-07-09 | -$59.74K 10-Q · filed 2013-11-13 | |||||
| 2012-09-30 | $0.00 10-Q · filed 2013-11-13 | $0.00 10-Q · filed 2013-11-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Veradermics, Inc (MANE) | United States | $4.839B |